Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions
Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions
复制标题
DOI：
10.1002/hed.25930
复制
发表时间：
2019-10-01
影响因子：
2.9
通讯作者：
Lou, Pei-Jen
中科院分区：
文献类型：
--
作者：
Kao, Hsiang-Fong;Lou, Pei-Jen
背景免疫检查点抑制剂（ICIs）可以重振T细胞并激活免疫系统以消除癌细胞。头颈鳞状细胞癌（HNSCC）是一种预后不良的恶性肿瘤。 ICI 在 HNSCC 治疗中的作用正在显现。方法我们回顾了程序性死亡1（PD-1）和PD-配体-1（PD-L1）单克隆抗体治疗HNSCC的研究结果。还回顾了正在进行的抗 PD-1 和抗 PD-L1 试验。结果纳武单抗对铂类难治性 HNSCC 患者显示出显着的总体生存获益。对于铂敏感或一线患者，与 EXTREME（西妥昔单抗-铂-氟尿嘧啶）相比，派姆单抗单药治疗（PD-L1 综合阳性评分 >= 20 的患者）或派姆单抗-铂-氟尿嘧啶可改善总生存期。许多HNSCC研究将抗PD1/PD-L1疗法与各种抗癌药物或放射疗法相结合，以提高治疗效果。结论 ICI 证明了其对 R/M HNSCC 患者的疗效。 ICI 的纳入对 HNSCC 的治疗前景产生了巨大影响。
Background Immune checkpoint inhibitors (ICIs) can reinvigorate T cells and activate the immune system to eliminate cancer cells. Head and neck squamous cell carcinoma (HNSCC) is a malignancy with a poor prognosis. The roles of ICIs for HNSCC treatments are emerging. Method We reviewed the study results of Programmed-Death 1 (PD-1) and PD-ligand-1 (PD-L1) monoclonal antibodies for HNSCC. The ongoing trials of anti-PD-1 and anti-PD-L1 were also reviewed. Results Nivolumab showed a significant overall survival benefit in platinum-refractory HNSCC patients. For platinum-sensitive or first-line patients, pembrolizumab monotherapy (patients with PD-L1 Combined Positive Score >= 20) or pembrolizumab-platinum-fluorouracil improved overall survival vs the EXTREME (cetuximab-platinum-fluorouracil). Many HNSCC studies have combined anti-PD1/PD-L1 therapy with various anticancer agents or radiotherapy to improve treatment efficacy. Conclusion ICIs demonstrate their efficacies for R/M HNSCC patients. The incorporation of ICIs showed a great impact on the treatment landscape of HNSCC.